We need to do better for people with advanced cancer. Cancer clinical trials are the way we have made progress, and the only path ahead for people where our current tools fail them. In this conversation, I’ll share with you what I’ve learned in 25 years of doing cancer clinical trials. I’ll explain how every study volunteer helps make life better for other people. I’ll share some stories of the successes I’ve seen, and why I am more hopeful than ever that the future will be even better. I will touch on the most promising ahead – immune modulation, “bespoke” immunotherapies, and the liquid biopsies. www.albertacancerclinicaltrials.ca John Mackey is a professor in the Department of Oncology at the University of Alberta and a Medical Oncologist at the Cross Cancer Institute in Edmonton. He previously directed the Clinical Trials Unit at the CCI and was executive director of TRIO, a global clinical trial organization with more than forty thousand participants in interventional cancer clinical trials (www.trioncology.org). He chairs the Alberta Pre-Phase I Cancer Program (www.prephaseone.com) to bring new anticancer therapies from academic laboratories into clinical testing. He is working to develop a first in class new anticancer therapy exploiting inhibition of N-myristoyl transferases (www.pacylex.com) and a revolutionary light microscopy technique for tissue analysis (www.illumisonics.com). He holds six patents, has founded three biotechnology / medical technology companies and has (co)authored 300 peer-reviewed manuscripts. He was inducted as a Fellow of the Canadian Academy of Health Sciences.
Charitable #: 80901 3675 RR0001
Wellspring Organization Websites
Receive E-News Updates
